Silence Therapeutics: SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia
Horizon Discovery is a world-leader in the application of gene editing and gene modulation technologies and is at the centre of innovation and drug discovery.
Our senior team has worked together for many years, delivering high-level strategic healthcare consultancy with seamless execution and unrivalled market intelligence.
Consilium Healthcare - RT @HorizonGenomics: You've done your #CRISPR transfection... what's next? https://t.co/x7fEGPn3zC https://t.co/x4Yhw4Bt8I